Diabetes Drug Prices Soar as Pharma Pursues Profits Over Access

• Drug companies pricing diabetes drugs up to 400 times higher than production costs, per new study • Modern insulin pens could be affordable globally if companies prioritized people over profits • New diabetes drugs like Ozempic are unaffordable despite demand in poorer countries • Pre-filled insulin pens could be profitably sold for under $1 but have markup up to $90 • Drug companies claim efforts to improve access but keep prices high for astronomical profits